Sept. 15, 2026
Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard.You can reach Adam on Signal at stataf.54.
Vera Therapeutics said Tuesday that its recently approved drug Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in patients with a chronic autoimmune kidney disease, according to final, two-year results from a Phase 3 clinical trial.
In July, the Food and Drug Administrationgranted accelerated approvalto Trutakna for the treatment of IgA nephropathy, or IgAN, a disease caused by the buildup of immune antibodies in the kidneys. The condition leads to progressive loss of kidney function and potentially organ failure requiring dialysis.
Advertisement
With the final data from the study in hand, Vera said it will seek full approval of the drug from the FDA during the fourth quarter.
STAT+ Exclusive Story
Already have an account?Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account?Log in
Monthly
$39
Totals $468 per year
$39/monthGet StartedTotals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 monthsGet StartedThen $399/year
Annual
$399
Save 15%
$399/yearGet StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A QuoteRequest A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/yearGet Started$300 Annually per user
View All PlansTo read the rest of this story subscribe to STAT+.
SubscribeLog Inbiotechnology,
drug development,
Pharmaceuticals,
STAT+Submit a correction requestReprintsSenior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcastThe Readout Loudand author of the newsletterAdam’s Biotech Scorecard.You can reach Adam on Signal at stataf.54.
STAT+ Newsletter
Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world
